What an exhilarating start to the year! The spotlight now shines on companies wielding cutting-edge technologies that are revolutionizing a myriad of industries, from healthcare to technology and beyond. These are the trailblazers that are reshaping the world as we know it. Some of these stocks have already achieved substantial success, with ample room for further growth. In other cases, these stocks have been dormant, biding their time before they burst into the limelight.

As you embark on your investment journey in this new year, it would be prudent to consider adding a few of these captivating innovators to your portfolio. For the cautious investor, dipping a toe with a small position in one or two may be worth the while, while the more daring investor may eye larger positions. Let’s delve into five revolutionary stocks that hold the potential to invigorate your portfolio as early as this year.

Image source: Getty Images.

1. CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ: CRSP) has just achieved a groundbreaking milestone by securing approval for its inaugural product, Casgevy, designed for treating blood disorders. This regulatory vindication also made history as the first global nod for a therapy harnessed from CRISPR gene editing.

This innovative technique revolves around slicing DNA at specific sites, triggering a corrective process that repairs genes responsible for certain ailments. The astounding potential lies in its capacity to produce lasting cures, vastly enhancing the quality of life for patients. Casgevy, sanctioned for sickle cell disease, heralds a revolutionary era and CRISPR Therapeutics’ pipeline teems with other gene-editing candidates that may birth further game-changing treatments.

The promise of this technology, coupled with the anticipated influx of Casgevy revenue this year, positions CRISPR Therapeutics as an innovative force poised for ascension in the ensuing months and beyond.

2. Ginkgo Bioworks

Ginkgo Bioworks (NYSE: DNA) operates on the covert fringes, driving advancements in assorted sectors such as pharmaceuticals, materials, and agriculture. Its domain involves engineering organisms that empower companies in these sectors to craft superior products.

The organism maestro has inked numerous high-profile collaborations, with its recent pact for RNA therapeutics development with pharmaceutical behemoth Pfizer potentially reaping Ginkgo up to $331 million. Concurrently, the company’s active projects have notched up a 36% surge year over year in the third quarter.

Ginkgo’s cell engineering revenue soared by double-digit percentages in the most recent quarter. While the company is yet to turn a profit, its $1 billion cash reserve offers a multiyear runway to steer itself towards that goal.

These combined factors position Ginkgo’s shares, currently trading at less than $2 each, as a prospective opportunity to invest in a budding performer.

3. Alphabet

Alphabet‘s (NASDAQ: GOOG) (NASDAQ: GOOGL) shares ascended last year, but this foremost technology stalwart exhibits the fortitude to perpetuate its winning streak. As the parent entity of the search-engine titan, Google, the company magnetizes a throng of advertisers eager to connect with their target audiences – you and me.

Amid concerns that a slackening economy would crimp ad outlays, Alphabet adeptly circumvented a brief advertising lull to sustain overall revenue growth.

Why bet on sustained revenue expansion? To begin, Google commands 91% of the search market and has ingrained itself into our search habits; altering habits is famously challenging. Furthermore, as part of its foray into artificial intelligence (AI), Alphabet recently unveiled its most potent AI model to date. Currently undergoing trials in Google search, Gemini aspires to elevate the search experience to new echelons.

All these facets render Alphabet an enticing prospect at a mere 24 times forward earnings estimates, with ample room for further expansion in its stock value.

4. Teladoc Health

Teladoc Health (NYSE: TDOC) weathered a rough patch in the past couple of years. Despite revenue gains, investors fretted over the telemedicine titan’s struggle to attain profitability. The detrimental impact of billions of dollars in non-cash goodwill impairment charges tied to an acquisition only exacerbated the situation.

Yet, Teladoc seized the reins earlier this year, endeavoring to harmonize its pursuit of revenue growth with that of profitability. This initiative has borne fruit, with the company outstripping or matching expectations in recent quarters.

Presently, Teladoc is escalating its endeavors by initiating an exhaustive appraisal of its entire business operations. The aim is to channel investments and attention towards its primary focus of comprehensive, holistic care. In its latest earnings report, the company intimated that this move could catalyze a resurgence in its stock performance as well.

Trading near its historical nadir in terms of sales multiples, Teladoc beckons as a prime overhaul-narrative purchase.

TDOC PS Ratio data by YCharts.

5. Tesla

Tesla‘s (NASDAQ: TSLA) stock soared last year, but this electric vehicle (EV) luminary could continue to ascend in 2024 – and more crucially, in the long haul.

The company has reached a pivotal juncture that may exert pressure on immediate growth; for instance, it is plowing investments into AI and endeavors to slash costs over the long term. Despite that, Tesla’s ambition to be a leader in electrification and autonomous driving technology, coupled with its robust brand cachet, positions it as an enduring force in the EV landscape.